| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | N/A |
Will This Send Novartis Stock Soaring?
https://www.fool.com/investing/2020/01/27/will-this-send-novartis-stock-soaring.aspx?source=iedfolrf0000001
Jan 27, 2020 - The company recently received some great news about its cholesterol drug.
0
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
http://www.zacks.com/stock/news/731626/pharma-stock-roundup-jjs-mixed-q4-roche-novartis-new-drugs-approval-in-eu?cid=CS-ZC-FT-analyst_blog|stock_roundup-731626
Jan 24, 2020 - J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
0
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
http://www.zacks.com/stock/news/730536/jazz-jazz-submits-nda-for-xyrem-follow-on-candidate-jzp-258?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-730536
Jan 23, 2020 - Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
0
STMicroelectronics NV (STM) CEO Jean-Marc on Q4 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4318571-stmicroelectronics-nv-stm-ceo-jean-marc-on-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts
Jan 23, 2020 - STMicroelectronics NV (NYSE:STM) Q4 2019 Earnings Conference Call January 23, 2020, 03:30 ET Company Participants Celine Berthier - Group VP, IR Jean-Marc - President & CEO Lorenzo Grandi - Presid
0
ASML HOLDING NV (ASML) Q4 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2020/01/22/asml-holding-nv-asml-q4-2019-earnings-call-transcr.aspx?source=iedfolrf0000001
Jan 22, 2020 - ASML earnings call for the period ending December 31, 2019.
0
NV Energy seeking proposals for Nevada renewable energy projects
https://seekingalpha.com/news/3533338-nv-energy-seeking-proposals-for-nevada-renewable-energy-projects?utm_source=feed_news_all&utm_medium=referral
Jan 21, 2020 - Berkshire Hathaway Energy's (BRK.A, BRK.B) NV Energy says it is calling for proposals to add renewable energy projects that are compliant with Nevada's renewable portfolio standards.The company says i
0
Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe
http://www.zacks.com/stock/news/728495/novartis-nvs-gets-approval-for-ms-drug-mayzent-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-728495
Jan 21, 2020 - Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
0
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
http://www.zacks.com/stock/news/727955/jazzs-jazz-new-sleep-drug-sunosi-gets-approval-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-727955
Jan 21, 2020 - Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
0
Is Novartis AG (NVS) A Suitable Pick for Value Investors?
http://www.zacks.com/stock/news/726524/is-novartis-ag-nvs-a-suitable-pick-for-value-investors?cid=CS-ZC-FT-analyst_blog|value_stocks-726524
Jan 20, 2020 - Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.
0
Schlumberger NV (SLB) Q4 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2020/01/17/schlumberger-nv-slb-q4-2019-earnings-call-transcri.aspx?source=iedfolrf0000001
Jan 17, 2020 - SLB earnings call for the period ending December 31, 2019.
0
Page 1>